Background: HCC is the second leading cause of cancer-related deaths worldwide. Sorafenib (SFN) has been the backbone of advanced HCC treatment over the past decade. Since the mean age of HCC presentation is between 50 and 60 years, data on SFN use in the elderly patients (pts) remain scarce due to underrepresentation of this population in pivotal clinical trials. Thus, the treatment of elderly HCC pts represents a clinical challenge given the concomitance of advanced age with chronic hepatopathy, 
Background: Dermatologic adverse events (DAE) are frequently experienced in patients under sorafenib. Although the majority appear as rash or hand-foot reaction, some patients may present SL requiring biopsy or local procedures that may impact in the treatment. While there are series of patients with melanoma and BRAF inhibitors presenting SL, there is no information on HCC patients with sorafenib. Methods: We analyzed a prospective database of patients with HCC treated with sorafenib. Patients who developed biopsed SL were included and the pathology samples were reviewed. Results: Between oct-2007 and jan-2018, 313 patients were treated with sorafenib (54.6% BCLC-C, 88.7% ECOG-PS0 and 83.6% CPA), 88 (28.1%) presented DAE in the first 60 days (eDAE) and 24 (7.7%) developed SL submitted to excisional biopsy. From the 24 patients, 33 SL were biopsied and 5 patients presented more than 1 SL. Most of the patients with SL were male (79.2%), CPA (87.5%), HCV etiology (87.5%) and 2 had liver transplantation. The median time from sorafenib initiation until SL biopsy was 8.5 months (IQR 4.4 to 18.1). SL are described in the table. Lymphocyte proliferation at the interface between the SL and dermis was noted in 61.1%. The median treatment duration (MTD) and OS in the whole cohort were 6.5 months .9] and 13.6 months [CI95% 12.2-15.6], respectively. For the subgroup with SL, the MTD and OS was 12.5 [9.5 -22.0] and 26.5 months [CI95% 17.0 -43.9], respectively. For those with both eDEA and SL, the MTD and OS was 17.9 months [7.7-28.9 ] and 26.5 [22.0-51.6] respectively. There was no permanent discontinuation related to the SL. Background: The SHARP and Asia-Pacific (AP) trials showed that S improves OS compared to placebo in advanced HCC. However, OS was worse in the AP trial, which included predominantly East Asian (EA) patients. The purpose of this study was to determine whether ethnicity affects OS in patients with advanced HCC being treated with S. Methods: Patients who received S for the treatment of HCC between 01/01/08 and 30/06/16 in the provinces of British Columbia and Alberta, as well as Princess Margaret Cancer Centre and Sunnybrook Odette Cancer Centre in Toronto, Ontario were included. Patient demographics and clinical variables were retrospectively collected. Patients were dichotomized by ethnicity as either EA or not according to a validated list of surnames. Survival outcomes were assessed with KaplanMeier curves and compared with the log-rank test. A Cox-proportional hazard model was constructed with ethnicity and relevant clinical characteristics to assess their impact on survival. Results: A total of 757 patients were included. Mean age was 64 years. 81% men, 36% East Asian, and 86% Child-Pugh (CP) A at initiation of S. Underlying cause of liver disease was 31% hepatitis B Virus (HBV) and 30% hepatitis C virus (HCV). Majority of patients had a performance status of 0 (30%) or 1 (58%). EA compared to non-EA were more likely to have HBV (68 vs 11%) and less likely to have HCV (13 vs 39%), p < 0.01. Median OS was 8.6 months for EAs and 9.6 months in non-EAs (p ¼ 0.89). On multivariate analysis, ethnicity (HR 1.01, 95% CI 0.82 -1.27, p ¼ 0.89) was not a significant prognostic factor for OS. However, no previous localized treatment (HR 1.66 95%CI 1.39 -1.99, p < 0.01), higher ECOG (HR 1.63 95% CI 1.34-1.97. p < 0.01), CP B at initiation of S (HR 1.72 95% CI 1.34 -2.20, p < 0.01) and HBV compared to HCV (HR 1.39 95% CI 1.08-1.80, p ¼ 0.01) were associated with worse survival. Conclusions: Ethnicity does not affect OS in HCC patients treated with S. However, patients treated with S who have a history of HCV appear to have a better OS than those with HBV. Higher baseline ECOG, no previous localized treatments and CP B liver function appear to negatively affect OS. Legal entity responsible for the study: CHORD consortium. 
